|
Match
|
Document |
Document Title |
|
|
US20110060017 |
NOVEL 1,2,3-TRIAZOLE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS
This invention relates to novel 1,2,3-triazole derivatives, which are found to be modulators of the nicotinic acetyl-choline receptors. Due to their pharmacological profile, the compounds of the... |
|
|
US20150011591 |
BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT
The present invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof; wherein R, R1, R2, R3, R4, m, and n are as defined herein, to pharmaceutical... |
|
|
US20130172389 |
BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT
The present invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof; wherein R, R1, R2, R3, R4, m, and n are as defined herein, to pharmaceutical... |
|
|
US20150196540 |
NMDA RECEPTOR MODULATORS AND USES RELATED THERETO
This disclosure relates to NMDA modulators and used related thereto such as for treatment of central nervous system disorders. In certain embodiments, compounds disclosed herein are NR2C... |
|
|
US20110294856 |
NOVEL OXADIAZOLE DERIVATIVES AND THEIR MEDICAL USE
This invention relates to novel oxadiazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the... |
|
|
US20150166571 |
Heteroaryl Compounds and Methods of Use Thereof
Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided... |
|
|
US20140304842 |
RED-SHIFTED LUCIFERINS AND METHODS OF USING SAME
Novel red-shifted luciferin derivatives and uses of those compounds are provided. |
|
|
US20130231332 |
SMALL MOLECULE INHIBITORS OF EBOLA AND LASSA FEVER VIRUSES AND METHODS OF USE
The present invention relates to compositions and methods for the treatment of infection by enveloped viruses, such as Ebola and Lassa fever viruses. |
|
|
US20110243850 |
PROBE FOR A BIOLOGICAL SPECIMEN AND LABELLING METHOD AND SCREENING METHOD USING THE PROBE
Provided is a novel probe for a biological specimen for labelling by itself and clearly visualizing one of a specific cell and a specific cell organ in a living body, the probe having excellent... |
|
|
US20120214824 |
PROTEOSTASIS REGULATORS
The present invention is directed to compounds of Formulae (I), (II), (III), (IV), (V), (VI), (VII), and (VIII), pharmaceutical compositions thereof and methods of use thereof in the treatment of... |
|
|
US20120058120 |
Targets for Growth Factor Signalling and Methods of Therapy
Methods of screening or designing therapeutic agents effective for the treatment of a transglutaminase-associated disease, disorder and/or condition are provided which include determining whether... |
|
|
US20120258048 |
OPTICAL FLUORESCENT IMAGING
Compounds and methods are disclosed that are useful for noninvasive imaging in the near-infrared (NIR) spectral range. The NIR is highly sensitive for tumor detection and tracking. The application... |
|
|
US20110306133 |
CULTURE MEDIUM AND METHOD FOR INDUCING DIFFERENTIATION INTO ADIPOCYTES
Disclosed are a culture medium, an additive, and a method for efficiently inducing the differentiation of mammalian somatic stem cells into cells having the characteristics of adipocytes under... |
|
|
US20150090639 |
HALOGEN-FREE IONIC LIQUIDS IN NAPHTHA DESULFURIZATION AND THEIR RECOVERY
Ionic liquids of the general formula C+A? where C+ represents an organic cation, specifically, but not limited to the imidazolium, pyridinium, isoquinolinium, ammonium types, which have aliphatic... |
|
|
US20150166543 |
PHENYL-UREA AND PHENYL-CARBAMATE DERIVATIVES AS INHIBITORS OF PROTEIN AGGREGATION
The present invention relates to certain phenyl-urea and phenyl-carbamate derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for preventing,... |
|
|
US20150194611 |
AIR-STABLE, BLUE LIGHT EMITTING CHEMICAL COMPOUNDS
We report the synthesis and characterization of four novel CCC—NHC pincer platinum(II) and palladium(II) complexes, which adopt a distorted square planar configuration. These complexes emit bright... |
|
|
US20120205554 |
AIR-STABLE, BLUE LIGHT EMITTING CHEMICAL COMPOUNDS
We report the synthesis and characterization of four novel CCC—NHC pincer platinum(II) and palladium(II) complexes, which adopt a distorted square planar configuration. These complexes emit bright... |
|
|
US20110152080 |
THIADIAZOLYLOXYPHENYLAMIDINES AND USE THEREOF AS FUNGICIDES
The present invention relates to thiadiazolyloxyphenylamidines of the general formula (I), to a process for the preparation thereof, to the use of the amidines according to the invention in... |
|
|
US20110143937 |
THIADIAZOLYLOXYPHENYLAMIDINES AND USE THEREOF AS FUNGICIDE
The present invention relates to thiadiazolyloxyphenylamidines of the general formula (I), to a process for the preparation thereof, to the use of the amidines according to the invention in... |
|
|
US20140235587 |
SUBSTITUTED PYRAZOLES AS SPHINGOSINE RECEPTOR MODULATORS
The present invention relates to substituted pyrazoles, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of... |
|
|
US20140228345 |
SUBSTITUTED PYRAZOLE AZETIDINES AS SPHINGOSINE RECEPTOR MODULATORS
The present invention relates to substituted pyrazole azetidines, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of... |
|
|
US20140228324 |
SUBSTITUTED DIHYDROPYRAZOLES AS SPHINGOSINE RECEPTOR MODULATORS
The present invention relates to substituted dihydropyrazoles, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of... |
|
|
US20110215715 |
CHRYSENE COMPOUNDS FOR BLUE OR GREEN LUMINESCENT APPLICATIONS
This invention relates to chrysene compounds that are useful in electroluminescent applications and are capable of blue or green emission. It also relates to electronic devices in which the active... |
|
|
US20120253044 |
Boron Compounds and Uses Thereof
Organoboron compounds are described that upon exposure to light absorb light and isomerize and form a dark-colored isomer. The dark-colored isomer converts back to the colorless isomer upon... |
|
|
US20130060049 |
METHOD FOR PREPARING (S)-4-HYDROXY-2-OXO-1-PYRROLIDINE ACETAMIDE
A preparation method of (S)-4-hydroxy-2-oxo-1-pyrrolidine acetamide is provided, which includes the steps of preparing the crude product and crystallizing, wherein acetone and water are used as... |
|
|
US20120071483 |
THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER DISEASE AND RELATED DISORDERS THROUGH A MODULATION OF CELL STRESS RESPONSE
The present invention relates to compositions and methods for the treatment of Alzheimer's disease and related disorders. More particularly, the invention relates to combined therapies that... |
|
|
US20150209330 |
METHOD AND AGENT FOR THE TREATMENT AND PROPHYLAXIS OF DISEASES CAUSED BY (+)RNA-CONTAINING VIRUSES
The invention relates to medicine and concerns a method for the prophylaxis or treatment of diseases caused by (+)RNA-containing viruses which involves the use of an effective amount of glutaryl... |
|
|
US20140018377 |
Aminopropenoates as Fungicides
This application claims priority to European Patent Application No. 09173304.8, filed Oct. 16, 2009, and the benefit of U.S. Provisional Application No. 61/253,091, filed Oct. 20, 2009, the... |
|
|
US20110039802 |
NPY Y5 ANTAGONIST
The present invention provides a pharmaceutical composition for use as an NPY Y5 receptor antagonist comprising a compound of the formula (I): wherein R1 is lower alkyl, cycloalkyl or the like, R2... |
|
|
US20130144068 |
Methods for the Sterilization of Bendamustine
The present application is directed to methods of sterilizing bendamustine and its pharmaceutically acceptable salt forms. Preferred sterilization methods include dry heat sterilization, gamma... |
|
|
US20130028843 |
KALLIKREIN 7 MODULATORS
The present invention relates to the crystal structure of the serine protease kallikrein 7 and to the use of this crystal structure in drug discovery. The present invention also relates to... |
|
|
US20120122810 |
Fused Pentacyclic Polyethers
Disclosed are polycyclic polyether compounds of formula I and pharmaceutical compositions comprising such compounds. wherein R, OR1, and R2 are as defined herein. Also disclosed are methods of... |
|
|
US20120225871 |
SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY
Provided are small-molecule Trp-p8 modulators, including Trp-p8 agonists and Trp-p8 antagonists, and compositions comprising small-molecule Trp-p8 agonists as well as methods for identifying and... |
|
|
US20150251139 |
Methods to Enhance Separation Performance of Metal-Organic Framework Membranes
A method produces a metal-organic framework on a surface of another metal-organic framework. One embodiment comprises contacting the first metal-organic framework with a ligand and solvent... |
|
|
US20130315836 |
NOVEL CELL-PENETRATING MARKERS OF APOPTOSIS
Provided herein are compounds useful for selectively labeling an apoptotic cell, and methods and assays using such compounds for the detection of an apoptotic cell in vivo or in a biological... |
|
|
US20130039854 |
MONOAMINE OXIDASE INHIBITORS AND METHODS FOR TREATMENT AND DIAGNOSIS OF PROSTATE CANCER
A mechanism of monoamine oxidases (MAOs) driven epithelium-to-mesenchymal transition (EMT) is disclosed. Also disclosed are methods for treating cancer by inhibiting or suppressing MAOs in cancer... |
|
|
US20090292128 |
PRODUCTION OF LOW COLOR POLYETHERIMIDES
The production of low color polyetherimides, including its intermediates, such as bisimides and diaryl diether dianhydrides, may be affected by producing an improved purity intermediate of... |
|
|
US20150024032 |
METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA
Embodiments of the invention include methods of treating, preventing, and/or reduce the risk or severity of a condition selected from the group consisting of muscle wasting, muscle weakness,... |
|
|
US20130045930 |
CRYSTALLINE FORMS OF THE MONO-SODIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN
The present invention relates to crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan, pharmaceutical compositions comprising them, their use in the treatment of various... |
|
|
US20130045929 |
CRYSTALLINE FORMS OF THE MONO-SODIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN
The present invention relates to crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan, pharmaceutical compositions comprising them, their use in the treatment of various... |
|
|
US20130005987 |
CRYSTALLINE FORMS OF THE MONO-SODIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN
The present invention relates to crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan, pharmaceutical compositions comprising them, their use in the treatment of various... |
|
|
US20130041163 |
PRODUCTION OF ATORVASTATIN LOW IN LACTONE IMPURITIES
The present invention relates to a method for the production of atorvastatin having decreased levels of impurity (3) by means of a pH-controlling step. |
|
|
US20140051675 |
MODULATORS OF CELLULAR ADHESION
The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in... |
|
|
US20120035154 |
Modulators of Cellular Adhesion
The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in... |
|
|
US20110124669 |
Modulators of Cellular Adhesion
The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in... |
|
|
US20140128615 |
Preservation Of Ergothioneine
Compositions comprising ergothioneine and a trimethylamine absorber are provided. Also provided are methods for preventing, reducing or minimizing the fishy, amine odor, due to trimethylamine,... |
|
|
US20140378680 |
SPIRO-OXINDOLE MDM2 ANTAGONISTS
Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists... |
|
|
US20140148494 |
SPIRO-OXINDOLE MDM2 ANTAGONISTS
Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists... |
|
|
US20130296303 |
SPIRO-OXINDOLE MDM2 ANTAGONISTS
Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists... |
|
|
US20120289494 |
SPIRO-OXINDOLE MDM2 ANTAGONISTS
Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists... |